This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T.
Timeframe: Within 7 days after vaccination
To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T.
Timeframe: Within 28 days after vaccination
To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T.
Timeframe: Throughout the study period, from enrollment to 6 months follow up
To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T.
Timeframe: Screening and day 8